Sep_363856
Total Payments
$1.8M
Transactions
17
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $1.8M | 17 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.8M | 17 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| SEP-363856 | Sunovion Pharmaceuticals Inc. | $1.8M | 0 |
Top Doctors Receiving Payments for Sep_363856
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Durham, NC | $1.8M | 17 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.8M
- Total Doctors 0
- Transactions 17
About Sep_363856
Sep_363856 is a drug associated with $1.8M in payments to 0 healthcare providers, recorded across 17 transactions in the CMS Open Payments database. The primary manufacturer is Sunovion Pharmaceuticals Inc..
Payment data is available from 2017 to 2017. In 2017, $1.8M was paid across 17 transactions to 0 doctors.
The most common payment nature for Sep_363856 is "Unspecified" ($1.8M, 100.0% of total).
Sep_363856 is associated with 1 research study, including "SEP-363856" ($1.8M).